Healthcare provider profile · identity verified

John R Mathis, M.D.

Internal Medicine · ANACORTES, WA · NPI 1780754739

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	389	109
Levothyroxine Sodium	Levothyroxine Sodium	343	83
Lisinopril	Lisinopril	327	90
Amlodipine Besylate	Amlodipine Besylate	285	75
Omeprazole	Omeprazole	233	68
Simvastatin	Simvastatin	206	56
Metoprolol Succinate	Metoprolol Succinate	199	57
Hydrochlorothiazide	Hydrochlorothiazide	194	57
Losartan Potassium	Losartan Potassium	187	54
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	163	19
Rosuvastatin Calcium	Rosuvastatin Calcium	134	40
Metformin Hcl	Metformin Hcl	126	35
Tamsulosin Hcl	Tamsulosin Hcl	123	35
Potassium Chloride	Potassium Chloride	119	37
Lorazepam	Lorazepam	100	22
Trazodone Hcl	Trazodone Hcl	96	27
Allopurinol	Allopurinol	95	24
Gabapentin	Gabapentin	93	32
Eliquis	Apixaban	87	24
Furosemide	Furosemide	87	32
Albuterol Sulfate Hfa	Albuterol Sulfate	83	27
Clonazepam	Clonazepam	82	12
Citalopram Hbr	Citalopram Hydrobromide	79	22
Prednisone	Prednisone	77	30
Carvedilol	Carvedilol	72	15
Atenolol	Atenolol	69	19
Glipizide	Glipizide	56	17
Quetiapine Fumarate	Quetiapine Fumarate	56	suppressed
Duloxetine Hcl	Duloxetine Hcl	54	15
Fluticasone Propionate	Fluticasone Propionate	54	20
Alprazolam	Alprazolam	48	13
Sertraline Hcl	Sertraline Hcl	45	13
Chlorthalidone	Chlorthalidone	43	14
Warfarin Sodium	Warfarin Sodium	43	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	15
Famotidine	Famotidine	42	12
Metoprolol Tartrate	Metoprolol Tartrate	42	12
Pantoprazole Sodium	Pantoprazole Sodium	42	12
Estradiol	Estradiol	40	13
Meloxicam	Meloxicam	40	14
Glipizide Er	Glipizide	39	suppressed
Spironolactone	Spironolactone	39	13
Bupropion Xl	Bupropion Hcl	38	15
Clopidogrel	Clopidogrel Bisulfate	36	suppressed
Ozempic	Semaglutide	35	suppressed
Tramadol Hcl	Tramadol Hcl	34	11
Oxycodone Hcl	Oxycodone Hcl	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Primidone	Primidone	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	27	suppressed
Baclofen	Baclofen	27	suppressed
Lovastatin	Lovastatin	26	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Dextroamphetamine Sulfate Er	Dextroamphetamine Sulfate	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	14
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Felodipine Er	Felodipine	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Nystatin	Nystatin	19	11
Pregabalin	Pregabalin	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Solifenacin Succinate	Solifenacin Succinate	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	16
Alfuzosin Hcl Er	Alfuzosin Hcl	18	suppressed
Diazepam	Diazepam	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	14
Alendronate Sodium	Alendronate Sodium	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Progesterone	Progesterone, Micronized	16	suppressed
Dexamethasone	Dexamethasone	15	11
Finasteride	Finasteride	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	14	suppressed
Naproxen	Naproxen	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Estradiol (Once Weekly)	Estradiol	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Torsemide	Torsemide	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error